share_log

科伦博泰生物-B(06990.HK)：创新药物注射用SKB518新药临床试验申请获国家药监局批准

Kolon Life Science-B (06990.HK): The clinical trial application for the injection SKB518 of innovative drug has been approved by the National Medical Products Administration.

Gelonghui Finance ·  Jun 17 16:48

On June 17th, Gelunhui announced that Kaitlyn Borges Biological-B (06990.HK) had received the clinical trial notification for the innovative pharmaceutical SKB518 developed by the company approved by the National Medical Products Administration (NMPA) Drug Evaluation Center on June 17, 2024.

SKB518 for injection is an innovative antibody-drug conjugate developed by the company using the OptiDCTM platform technology based on the biological characteristics of the target. It has shown good efficacy and safety windows in preclinical studies and is intended for the treatment of advanced solid tumors.

The company will organize the SKB518 clinical trial in accordance with the requirements of the clinical trial notification issued by the NMPA.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment